• Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected in 2027
  • Additional compassionate care work now initiated by the Nuclear Medicine Research Institute in South Africa utilizing 225Ac-loaded DLL3 Radio-DARPin, highlighting the versatility of DARPins as isotope agnostic vectors
  • FIH imaging for MP0726, Radio-DARPin targeting MSLN, planned to start in H2 2026
  • New target nomination in H2 2026, with two INDs planned in 2027